VACCINEXPAR |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.65 USD | -3.93% |
|
-31.62% | -50.04% |
| Apr. 12 | Vaccinex, Inc. announced that it has received $1.75 million in funding | CI |
| Apr. 02 | Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | 275K | Sales 2023 | 570K | Capitalization | 8.31M |
|---|---|---|---|---|---|
| Net income 2022 | -19M | Net income 2023 | -20M | EV / Sales 2022 | 95.4 x |
| Net cash position 2022 | 5.91M | Net cash position 2023 | 1.29M | EV / Sales 2023 | 12.3 x |
| P/E ratio 2022 |
-1.37
x | P/E ratio 2023 |
-0.21
x | Employees | 39 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.93% | ||
| 1 week | -31.62% | ||
| Current month | -37.25% | ||
| 1 month | -43.29% | ||
| 3 months | -39.61% | ||
| 6 months | -63.50% | ||
| Current year | -50.04% |
1 week
4.43
6.90
1 month
4.438.63
Current year
4.4313.02
1 year
4.43100.80
3 years
4.43688.80
5 years
4.432 568.30
10 years
4.432 568.30
| Managers | Title | Age | Since |
|---|---|---|---|
Maurice Zauderer
FOU | Founder | 78 | 96-12-31 |
Elizabeth Evans
COO | Chief Operating Officer | 52 | 01-04-30 |
Ernie Smith
CTO | Chief Tech/Sci/R&D Officer | 52 | 01-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bala S. Manian
BRD | Director/Board Member | 77 | 04-11-30 |
Albert Friedberg
CHM | Chairman | 77 | 96-12-31 |
Chrystyna Stecyk
BRD | Director/Board Member | 61 | 20-05-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 4.65 | -3.93% | 9 761 |
| 24-04-17 | 4.84 | +1.68% | 6,057 |
| 24-04-16 | 4.76 | -5.37% | 11,217 |
| 24-04-15 | 5.03 | -17.54% | 35,834 |
| 24-04-12 | 6.1 | -10.29% | 11,507 |
Delayed Quote Nasdaq, April 18, 2024 at 01:41 pm EDT
More quotes
Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab's mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Sector
-
- Stock Market
- Equities
- VCNX Stock
